Рет қаралды 169
Drs. Jeffrey Geske and Paul Friedman discuss the evolving landscape of therapies from treatment of hypertrophic cardiomyopathy. The dialogue includes novel therapies (myosin inhibitors), the evolving role of septal reduction therapy, and exploring unanswered questions.
Topics Discussed:
• Hypertrophic Cardiomyopathy
• Myosin Inhibitors
• Septal Reduction Therapy